NOT KNOWN FACTUAL STATEMENTS ABOUT SEMAGLUTIDE WEEK 1-6 BUNDLE

The demo attained both its Key endpoints, with semaglutide two.four mg demonstrating statistically significant and top-quality advancements in liver fibrosis without any worsening of steatohepatitis, and also resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH compared to placebo.oneI have the same dilemma as